Journal ArticleDOI
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
Bohuslav Melichar,Antoine Adenis,A. Craig Lockhart,Jaafar Bennouna,E. Claire Dees,Omar Kayaleh,Radka Obermannova,Angela DeMichele,Petr Zatloukal,Bin Zhang,Claudio Dansky Ullmann,Claudia Schusterbauer +11 more
Reads0
Chats0
TLDR
These data support further clinical assessment of alisertib in patients with solid tumours, particularly those with breast cancer and small-cell lung cancer.Abstract:
Summary Background Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. We aimed to investigate the safety and activity of single-agent alisertib in patients with predefined types of advanced solid tumours. Methods We did a multicentre phase 1/2 study at 40 centres in four countries (Czech Republic, France, Poland, and the USA). Here, we report results from phase 2; enrolment for the study began on Feb 16, 2010, and ended on May 3, 2013. Adult patients were eligible for the study if they had either breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, or gastro-oesophageal adenocarcinoma that had relapsed or was refractory to chemotherapy. Patients had to have undergone two or fewer previous cytotoxic regimens (four or fewer for breast cancer patients), not including adjuvant or neoadjuvant treatments. Enrolment followed a two-stage design: to proceed to the second stage, two or more objective responses were needed in the first 20 response-assessable patients in each of the five tumour cohorts. Alisertib was administered orally in 21-day cycles at the recommended phase 2 dose of 50 mg twice daily for 7 days followed by a break of 14 days. The protocol-specified primary endpoint was the proportion of patients with an objective response, assessed by Response Evaluation Criteria In Solid Tumors version 1.1 in the response-assessable population (ie, patients with measurable disease who received at least one dose of alisertib and had undergone at least one post-baseline tumour assessment). This completed trial is registered with ClinicalTrials.gov, NCT01045421. Findings By May 31, 2013, 249 patients had been treated, 53 with breast cancer, 60 with small-cell lung cancer, 26 with non-small-cell lung cancer, 55 with head and neck squamous-cell carcinoma, and 55 with gastro-oesophageal adenocarcinoma. Among response-assessable patients, an objective response was noted in nine (18%, 95% CI 9−32) of 49 women with breast cancer, ten (21%, 10−35) of 48 participants with small-cell lung cancer, one (4%, 0−22) of 23 patients with non-small-cell lung cancer, four (9%, 2−21) of 45 people with head and neck squamous-cell carcinoma, and four (9%, 2−20) of 47 individuals with gastro-oesophageal adenocarcinoma; all were partial responses. Adverse events were similar across tumour types. The most frequent drug-related grade 3–4 adverse events included neutropenia (n=107 [43%]), leukopenia (53 [21%]), and anaemia (26 [10%]). Serious drug-related adverse events were reported in 108 (43%) patients. Interpretation These data support further clinical assessment of alisertib in patients with solid tumours, particularly those with breast cancer and small-cell lung cancer. Funding Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.read more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Cell Cycle Proteins as Promising Targets in Cancer Therapy
Tobias Otto,Piotr Sicinski +1 more
TL;DR: The role of cell cycle proteins in cancer, the rationale for targeting them in cancer treatment and results of clinical trials, as well as the future therapeutic potential of various cell cycle inhibitors are discussed.
Journal ArticleDOI
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu,Matthew R. Guthrie,Stefanie Böhm,Johannes Brägelmann,Ismail Can,Paul M. Ballieu,Annika Marx,Julie George,Christine Heinen,Milind D. Chalishazar,Haixia Cheng,Abbie S. Ireland,Kendall E. Denning,Anandaroop Mukhopadhyay,Jeffery M. Vahrenkamp,Kristofer C. Berrett,Timothy L. Mosbruger,Jun Wang,Jessica L. Kohan,Mohamed E. Salama,Benjamin L. Witt,Martin Peifer,Roman K. Thomas,Roman K. Thomas,Jason Gertz,Jane E. Johnson,Adi F. Gazdar,Robert J. Wechsler-Reya,Martin L. Sos,Trudy G. Oliver +29 more
TL;DR: It is shown that Myc expression cooperates with Rb1 and Trp53 loss in the mouse lung to promote aggressive, highly metastatic tumors, that are initially sensitive to chemotherapy followed by relapse, similar to human SCLC.
Journal ArticleDOI
Targeting Mitosis in Cancer: Emerging Strategies
Carmen Dominguez-Brauer,Kelsie L. Thu,Jacqueline M. Mason,Heiko Blaser,Mark R. Bray,Tak W. Mak +5 more
TL;DR: The concept of exploiting the genomic instability of tumor cells through therapeutic inhibition of mitotic checkpoints is discussed, and it is believed this strategy has a high likelihood of success given its potential to enhance therapeutic index by targeting tumor-specific vulnerabilities.
Journal ArticleDOI
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari,Benjamin H. Lok,James Laird,John T. Poirier,Charles M. Rudin,Charles M. Rudin +5 more
TL;DR: Progress made in uncovering aspects of the biology of SCLC and its microenvironment that are defining new therapeutic strategies and offering renewed hope for patients are reviewed.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal Article
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
Hirokazu Watanabe,Morihito Okada,Yasushi Kaji,Miyako Satouchi,Yozo Sato,Yuichiro Yamabe,Hiroaki Onaya,Masahiro Endo,Miyuki Sone,Yasuaki Arai +9 more
TL;DR: This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with a focus on updated contents.
Journal ArticleDOI
Aurora A kinase (AURKA) in normal and pathological cell division.
TL;DR: The mitotic and non-mitotic functions of Aurora A are reviewed, Aurora A regulation in the context of protein structural information is discussed, and progress in understanding and inhibiting Aurora A in cancer is evaluated.
Journal ArticleDOI
Characterization of Alisertib (MLN8237), An Investigational Small Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
Mark Manfredi,Jeffrey Ecsedy,Arijit Chakravarty,Lee Silverman,Mengkun Zhang,Kara Hoar,Stephen G. Stroud,Wei Chen,Vaishali Shinde,Jessica Huck,Deborah R. Wysong,David A. Janowick,Marc L. Hyer,Patrick J. LeRoy,Rachel E. Gershman,Matthew D. Silva,Melissa S. Germanos,Joseph B. Bolen,Christopher F. Claiborne,Sells Todd B +19 more
TL;DR: Preclinical characterization of alisertib (MLN8237), a selective AAK inhibitor, is described, incorporating novel pharmacodynamic assays to quantitatively measure biomarkers of AAK inhibition in vivo and application of tumor imaging described here may be valuable for clinical evaluation of small-molecule inhibitors.
Related Papers (5)
Comprehensive genomic profiles of small cell lung cancer
Julie George,Jing Shan Lim,Se Jin Jang,Yupeng Cun,Luka Ozretić,Gu Kong,Frauke Leenders,Xin Lu,Lynnette Fernandez-Cuesta,Graziella Bosco,Christian Müller,Ilona Dahmen,Nadine Jahchan,Kwon-Sik Park,Dian Yang,Anthony N. Karnezis,Dedeepya Vaka,Ángela Torres,Maia Segura Wang,Jan O. Korbel,Roopika Menon,Sung-Min Chun,Deokhoon Kim,Matthew D. Wilkerson,Neil Hayes,David Engelmann,Brigitte M. Pützer,Marc Bos,Sebastian Michels,Ignacija Vlasic,Danila Seidel,Berit Pinther,Philipp Schaub,Christian Becker,Janine Altmüller,Jun Yokota,Takashi Kohno,Reika Iwakawa,Koji Tsuta,Masayuki Noguchi,Thomas Muley,Hans Hoffmann,Philipp A. Schnabel,Iver Petersen,Yuan Chen,Alex Soltermann,Verena Tischler,Chang-Min Choi,Yong-Hee Kim,Pierre P. Massion,Yong Zou,Dragana Jovanovic,Milica Kontic,Gavin M. Wright,Prudence A. Russell,Benjamin Solomon,Ina Koch,Michael Lindner,Lucia Anna Muscarella,Annamaria la Torre,John K. Field,Marko Jakopović,Jelena Knezevic,Esmeralda Castaños-Vélez,Luca Roz,Ugo Pastorino,O.T. Brustugun,Marius Lund-Iversen,Erik Thunnissen,Jens Köhler,Martin Schuler,Johan Botling,Martin Sandelin,Montserrat Sanchez-Cespedes,Helga B. Salvesen,Viktor Achter,Ulrich Lang,Magdalena Bogus,Peter M. Schneider,Thomas Zander,Sascha Ansén,Michael Hallek,Jürgen Wolf,Martin Vingron,Yasushi Yatabe,William D. Travis,Peter Nürnberg,Christian Reinhardt,Sven Perner,Lukas C. Heukamp,Reinhard Büttner,Stefan A. Haas,Elisabeth Brambilla,Martin Peifer,Julien Sage,Roman K. Thomas +95 more
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer,Lynnette Fernandez-Cuesta,Martin L. Sos,Julie George,Danila Seidel,Lawryn H. Kasper,Dennis Plenker,Frauke Leenders,Ruping Sun,Thomas Zander,Roopika Menon,Mirjam Koker,Ilona Dahmen,Christian Müller,Vincenzo Di Cerbo,Hans Ulrich Schildhaus,Janine Altmüller,Ingelore Baessmann,Christian Becker,Bram De Wilde,Jo Vandesompele,Diana Böhm,Sascha Ansén,Franziska Gabler,Ines Wilkening,Stefanie Heynck,Johannes M. Heuckmann,Xin Lu,Scott L. Carter,Kristian Cibulskis,Shantanu Banerji,Gad Getz,Kwon-Sik Park,Daniel Rauh,Christian Grütter,Matthias Fischer,Laura Pasqualucci,Gavin M. Wright,Zoe Wainer,Prudence A. Russell,Iver Petersen,Yuan Chen,Erich Stoelben,Corinna Ludwig,Philipp A. Schnabel,Hans Hoffmann,Thomas Muley,Michael Brockmann,Walburga Engel-Riedel,Lucia Anna Muscarella,Vito Michele Fazio,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erik Thunnissen,Egber Smit,Daniëlle A M Heideman,Peter J.F. Snijders,Federico Cappuzzo,C. Ligorio,Stefania Damiani,John K. Field,Steinar Solberg,Odd Terje Brustugun,Marius Lund-Iversen,Jörg Sänger,Joachim H. Clement,Alex Soltermann,Holger Moch,Walter Weder,Benjamin Solomon,Jean-Charles Soria,Pierre Validire,Benjamin Besse,Elisabeth Brambilla,Christian Brambilla,Sylvie Lantuejoul,Philippe Lorimier,Peter M. Schneider,Michael Hallek,William Pao,Matthew Meyerson,Matthew Meyerson,Julien Sage,Jay Shendure,Robert Schneider,Robert Schneider,Reinhard Büttner,Jürgen Wolf,Peter Nürnberg,Sven Perner,Lukas C. Heukamp,Paul K. Brindle,Stefan A. Haas,Roman K. Thomas +94 more
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Charles M. Rudin,Steffen Durinck,Eric Stawiski,John T. Poirier,Zora Modrusan,David S. Shames,Emily Bergbower,Yinghui Guan,James Shin,Joseph Guillory,Celina Sanchez Rivers,Catherine K. Foo,Deepali Bhatt,Jeremy Stinson,Florian Gnad,Peter M. Haverty,Robert Gentleman,Subhra Chaudhuri,Vasantharajan Janakiraman,Bijay S. Jaiswal,Chaitali Parikh,Wenlin Yuan,Zemin Zhang,Hartmut Koeppen,Thomas D. Wu,Howard M. Stern,Robert L. Yauch,Kenneth E. Huffman,Diego D Paskulin,Peter B. Illei,Marileila Varella-Garcia,Adi F. Gazdar,Frederic J. de Sauvage,Richard Bourgon,John D. Minna,Malcolm V. Brock,Somasekar Seshagiri +36 more
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James W. Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach +27 more
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura Saunders,Alexander J. Bankovich,Wade C. Anderson,Monette Aujay,Sheila Bheddah,KristenAnn Black,Desai Radhika Chetan,Paul Anthony Escarpe,Johannes Hampl,Amy Laysang,David R. Liu,Javier Lopez-Molina,Milly Milton,Albert Park,Marybeth A. Pysz,Hui Shao,Brian Slingerland,Torgov Michael,Samuel A. Williams,Orit Foord,Howard Philip Wilson,Jacek Jassem,Andrzej Badzio,Piotr Czapiewski,David H. Harpole,Afshin Dowlati,Pierre P. Massion,William D. Travis,M. Catherine Pietanza,M. Catherine Pietanza,John T. Poirier,John T. Poirier,Charles M. Rudin,Robert A. Stull,Scott J. Dylla +34 more